

# THE RESURGENCE OF HALLUCINOGEN DRUGS IN CLINICAL RESEARCH

MARÍA T. RIVERA-GARCÍA<sup>1,¶</sup> AND SILVIA L. CRUZ<sup>2,\*</sup>

<sup>1</sup>Plaza Health Center, Cascadia Health, Portland, Oregon, USA; <sup>2</sup>Department of Pharmacobiology, Center for Research and Advanced Studies (Cinvestav), National Polytechnic Institute, Mexico City, Mexico

¶The information presented in this paper represents the views of the authors, and does not necessarily reflect the opinion of Cascade Health.

## ABSTRACT

Since the dawn of civilization, ancient cultures have utilized hallucinogens from plants and fungi in the context of religious and healing practices. Recently, their use has expanded to other cultures. Hallucinogens are natural or synthetic substances that alter the perception of reality at nontoxic doses, producing intense psychological and physiological effects. The initial research on hallucinogens began in the 1950s. However, their non-medical use, studies without proper controls, and negative social opinion resulted in legal restrictions that limited their use for clinical and preclinical research for more than two decades. A renewed interest in studying hallucinogens as potential therapeutic agents for treating different psychiatric conditions has recently re-emerged. This review summarizes the effects of main hallucinogen drugs and their therapeutic potential. Classic hallucinogens such as LSD, dimethyltryptamine, psilocin, and mescaline have chemical structures similar to serotonin and directly activate 5-hydroxy-tryptamine (5-HT<sub>2A</sub>) receptors. Ketamine is a dissociative anesthetic with antagonist effects at the glutamatergic N-methyl-D-aspartate receptor, indirectly activating 5-HT<sub>2A</sub> receptors. Ketamine has rapid antidepressant effects and reduces suicidal ideation, but its effects are short-lasting. Other hallucinogens are under study. It is necessary to continue this research with a more rigorous methodology and include studying the long-term effects of psychedelics use. (REV INVEST CLIN. 2023;75(3):169-78)

**Keywords:** Lysergic acid diethylamide. LSD. N,N-dimethyltryptamine. Magic mushrooms. Peyote. Antidepressant effects.

## INTRODUCTION

Hallucinations are vivid perceptual experiences involving all sensory systems that occur without the input of actual stimuli. Thus, hallucinogens are drugs that induce cognitive and perceptual distortion of reality. Several ethnic groups have traditionally used hallucinogens in ritual settings, but this practice is now common in many modern societies. The scientific interest in the effects of hallucinogens in controlled clinical

settings has been documented since the late 1940s. In the 1950s, clinical research focused on studying LSD as a coadjuvant in psychotherapy and as a model for understanding psychosis and treating depression<sup>1</sup>. During the 1960s, there was a surge in hallucinogen use related to the social movements of the time. Later, the Controlled Substances Act of 1970 placed hallucinogens in Schedule I, the most restrictive category. In 1975, the U.S. National Institute of Mental Health withdrew the research funding for

\*Corresponding author:  
Silvia L. Cruz  
E-mail: slcruz@cinvestav.mx

Received for publication: 25-05-2023  
Approved for publication: 01-06-2023  
DOI: 10.24875/RIC.23000108

0034-8376 / © 2023 Revista de Investigación Clínica. Published by Permanyer. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

human studies on hallucinogens' effects. The primary reason was that clinical research (mainly pilot studies) conducted at that moment did not provide sufficient evidence of the safety or therapeutic efficacy of hallucinogen drugs for any psychiatric condition. After a pause of almost three decades, the scientific community resumed hallucinogen research in the 2000s with a particular interest in the therapeutic potential of these substances. As of today, only after marijuana, hallucinogens are the most used illicit drug among young adults in the U.S.<sup>2</sup>

Although hallucinating is a subjective experience known by humans through personal experience or eyewitnesses, the users' physiological alterations and the mechanism of action of hallucinogen drugs are a matter of extensive preclinical and clinical investigation. This paper aims to review the effects, mechanisms of action, risks, and therapeutic potential of main hallucinogens.

## CLASSIFICATION OF HALLUCINOGEN DRUGS

Many compounds can produce hallucinations at toxic doses. However, the pharmacological criteria to consider a drug as a hallucinogen, as originally proposed by Humphry Osmond in the 1950s, are the production of perceptual alterations of reality at otherwise non-toxic doses. Although there are several classifications of hallucinogens, for this review, we will distinguish two main classes (a) serotonergic hallucinogens, represented by the lysergic acid diethylamide or LSD, and (b) dissociative anesthetics such as ketamine and phencyclidine (PCP). Classic hallucinogens include LSD, psilocin (in "magic" mushrooms), and N,N-dimethyltryptamine (DMT, in ayahuasca), among others<sup>3</sup>. These compounds have chemical structures similar to serotonin (5-hydroxy-tryptamine, or 5-HT) because they are tryptamines, characterized by the presence of an indole group (a six-member ring attached to a five-member ring containing nitrogen). Mescaline (in peyote) is also a serotonergic hallucinogen, but has a different chemical structure, because it is a phenethylamine, not a tyramine. Dissociative anesthetics are PCP and ketamine. Based on their chemical structure, these drugs are cyclohexanone derivatives, also called arylcyclohexylamine derivatives (Fig. 1)<sup>4</sup>.

## EFFECTS OF CLASSIC HALLUCINOGENS


LSD is the prototypic classic hallucinogen. Its initial effects involve sympathomimetic responses, including increased blood pressure, accelerated heart rate and respiration, dry mouth, nausea, sweating, appetite loss, and pupil dilation. In general, within a relatively short time after the onset of these responses, individuals begin to experience illusions and visual hallucinations. These hallucinations are described as moving, bright, colorful figures, and geometric patterns. One common effect of hallucinogens is the crossover of senses, also called synesthesia, where smells may be heard, or colors may be tasted. Although less frequently, it is also possible to experience auditory hallucinations.

Hallucinogens also produce pronounced psychological changes described as an intense emotional insight, and transcendent or spiritual experiences. LSD subjective effects include mood swings (from a peaceful, hilarious state to an anxiety attack), attention impairment, misperception of time, and depersonalization/derealization. This last effect has been described as a sense of unreality and the sensation of being detached from the environment, body, thoughts, and feelings, which could be unpleasant, leading to severe anxiety. Ego dissolution, or a compromised sense of "self," also occurs, characterized by "the reduction in the self-referential awareness that defines normal waking consciousness, ultimately disrupting self-world boundaries and increasing feelings of unity with others' and one's surroundings"<sup>5,6</sup>. A common term used to summarize that someone is experiencing the effects of hallucinogens is "tripping," and an unpleasant experience is usually called a bad trip.

Although pharmacological factors (dose and tolerance) are determinants to experience the effects of hallucinogenic drugs, psychological factors also play a crucial role in their behavioral effects and subjective experience. The "set and setting" concept refers to the different response that a person can have to hallucinogens depending on mind state (e.g., relaxed, depressed, anxious) and the setting in which the person consumes the drug (e.g., alone or in groups, in familiar or unfamiliar situations, in a clinical setting or at a music festival)<sup>7</sup>.

Classic hallucinogens do not produce compulsive drug-seeking behavior, which is why they are not

Figure 1. Classification of main hallucinogen drugs. Classic hallucinogens have chemical structures similar to serotonin. They include LSD (a synthetic drug), DMT (ayahuasca's psychoactive substance), psilocin (obtained from *Psilocybe* fungi), and mescaline (the active substance in peyote). Phencyclidine (PCP) and ketamine are synthetic dissociative anesthetics with hallucinogen effects.



considered addictive. However, these substances can induce acute tolerance to their effects. Thus, a second dose within a short period after the first dose will not produce the same effects. This fast development of tolerance to a single dose lasts several days and limits the daily use of these substances. Classic hallucinogens differ in efficacy, potency (the amount of drug needed to produce a specific action), time to peak effects, and duration. The following sections review the effects and mechanisms of action of the main hallucinogens studied.

## LSD

LSD is an ergot derivative. Ergot is a black fungus (*Claviceps purpurea*) that grows on rye. Conventionally, in the regions where this fungus grew, pregnant women drank water infused with ergot to facilitate labor work. Ergot was also responsible for San Anthony's fire or ergotism, a condition characterized by

strong blood vessel constriction that could result in gangrene. Albert Hoffman synthesized LSD in 1938 while looking for ergot derivatives with therapeutic effects. However, he did not experience LSD's effects until 1943, when the formal research on hallucinogens began.

LSD is one of the most potent drugs known, with an effective oral dose of only 25-50 µg, although the doses available on the street market can reach up to 100-200 µg. The half-life of LSD (time needed to decrease 50% the drug concentration in bloodstream) is approximately 3-4 h, but its effects last longer, from 9 to 12 h, in most people<sup>8</sup>. LSD is available as tablets; however, due to its potency, it is usually diluted and applied to blotting papers, gummies, or sugar cubes that are dissolved in the mouth. Because LSD is a tryptamine, it has structural similarity to serotonin 5-HT and acts as a partial agonist of several 5-HT receptor subtypes (Table 1). Several pharmacological experiments indicate that the

Table 1. Affinity (Ki; nM) of serotonergic hallucinogens for various receptors. Based on reviews<sup>10,18,22,23</sup>

| Hallucinogen | 5 HT <sub>1A</sub> | 5HT <sub>2A</sub> | 5HT <sub>2C</sub> | D <sub>1</sub> | D <sub>2</sub> | TAAR1  |
|--------------|--------------------|-------------------|-------------------|----------------|----------------|--------|
| LSD          | 3                  | 3-4               | 15                | 310            | 25             | 10,000 |
| Psilocin     | 123                | 49                | 94                | >14,000        | 3700           | 1400   |
| DMT          | 75-183             | 127-237           | 360-424           | 6000           | 3000           | 15,000 |
| Mescaline    | 4100               | 6300              | 17,000            | >14,000        | >10,000        | 3000   |

TAAR1: trace-amine-associated receptor 1.

effects of LSD and other serotonergic hallucinogens are mainly mediated by 5HT<sub>2A</sub> receptors (see below). These receptors are highly expressed in the cortex, striatum, amygdala, hippocampus, and on layer V of cortical pyramidal neurons. Other molecular targets of LSD include dopamine D<sub>1</sub> and D<sub>2</sub> receptors<sup>9</sup>. At micromolar concentrations, LSD activates the trace-amine-associated receptor 1 (TAAR1), a relatively recently described receptor stimulated by the endogenous ligands tryptamine and β-phenylethylamine. Neurons and glial cells express mainly intracellular TAAR1 receptors, now recognized as molecular targets for many psychoactive substances<sup>10</sup>.

## AYAHUASCA – DMT

Ayahuasca is a liquid concoction traditionally used in ceremonies by Amazonian groups and members of syncretic religious groups, such as Santo Daimo in Brazil. More recently, ayahuasca has emerged as a commonly used beverage in Westernized countries, often without clear regulations. Ayahuasca is prepared by boiling water with the leaves of a bush (*Psychotria viridis*, also known as “chacrana”) and the stem or bark of the *Banisteriosis caapi* liana. The psychoactive substance contained in the leaves of *P. viridis* is DMT, another tryptamine similar to serotonin. In addition, *B. caapi* contains β-carbolines, also known as harmala alkaloids, which inhibit DMT metabolism, rendering it orally active<sup>11</sup>.

DMT is present in over 50 South American plants, including *Diplopterys cabrerana* and *Desmanthus illinoensis*. Small quantities are also present in humans. The concentration of DMT in *P. viridis* ranges between 0.1 and 0.66%. The amount of DMT in ayahuasca varies from 0.1 to 40 mg T<sup>12,13</sup>. DMT alone is

inactive orally due to its rapid deactivation through mono amino oxidase A (MAO-A) enzymatic action. This enzyme breaks down serotonin, dopamine, adrenaline, noradrenaline, and DMT, reducing bioavailability. MAO-A is present in the liver, gastrointestinal tract, blood, kidney, and brain, rendering DMT inactive when ingested. If DMT is smoked or insufflated, it produces an almost immediate effect that lasts less than an hour. When combined with MAO inhibitors, DMT blood concentrations are high enough to enter the brain. The β-carbolines contained in *B. caapi*: harmine, harmaline, and tetra-hydroxy-harmine (THH) inhibit MAO-A and are weak selective serotonin reuptake inhibitors (SSRI). Harmine also inhibits dopamine transporters, increasing extracellular dopamine levels. Other compounds in ayahuasca have antioxidant and anti-inflammatory actions<sup>14</sup>.

Ayahuasca and LSD produce similar effects, but their time course is different. Ayahuasca-induced effects begin 30-60 min after intake, reach maximal intensity between 1 and 2 h, and last approximately 4 h. Nausea, diarrhea, and vomiting are very common after drinking ayahuasca, but in the ceremonial context, these effects are considered a purifying purge for the body and soul. There is risk of dehydration, especially if users are far from medical services. Like other classical hallucinogens, DMT produces its actions through 5-HT<sub>2A</sub> receptor activation but is also an agonist or partial agonist of other receptors including the 5-HT<sub>1A</sub>, 5-HT<sub>2C</sub>, 5-HT<sub>6</sub>, 5-HT<sub>7</sub>, sigma1, and TAAR1 receptors (Table 1).

## MUSHROOMS – PSILOCYBIN AND PSILOCIN

Although hallucinogen drugs use is well documented in ancient cultures for religious and recreational

purposes, the Florentine Codex is the earliest known written record of “magic mushrooms” use. This ethnographic manuscript was compiled between 1529 and 1579 in Mesoamerica, particularly in the Aztec culture of Mexico<sup>7</sup>. There are more than 100 species of the *Psilocybe* gender of mushrooms. They grow in humid environments in Mexico, several regions of the US, Europe, Asia, and other countries worldwide.

*Psilocybe* mushrooms, also called magic or psychedelic mushrooms, were introduced to Western culture in the 1950s by R. Gordon Wasson, who published in a popular magazine his experience with psilocybin after participating in a Mazatecan ceremony in Mexico. In 1957, Albert Hoffman isolated psilocybin and psilocin from the mushroom species *Psilocybe mexicana*, a sacred mushroom known as “teonanacatl” (meaning God’s flesh) by the ancient Aztecs. A few years later, Sandoz Pharmaceuticals distributed Indocybin®, a pill containing 2 mg of psilocybin. Psychologists and psychiatrists used psilocybin in clinical practice and conducted research trials for approximately 10 years in the 1960s and 1970s. However, psilocybin was withdrawn from the pharmaceutical market in 1970 and placed in the Schedule I category, restricting its use in human research due to the lack of conclusive findings in the pioneer studies, the increasing use of psilocybin in non-controlled environments, and the crescent social negative perception<sup>7,15</sup>. The interest in psilocybin research re-emerged around the 2000s when several groups started testing it to treat psychiatric disorders, including anxiety, depression, and addiction. However, it was until 2020 that the legal status of psilocybin started changing in North America when Oregon became the first state in the US to legalize “magic mushrooms” consumption in supervised settings. These new regulations came into effect in January 2023. In 2022, Colorado enlisted as the second US state to legalize psilocybin mushrooms. When writing this review, California has a pending bill to legalize psilocybin and other hallucinogens, including LSD, mescaline, and DMT. In Mexico, psilocybin is illegal according to the “Ley General de Salud” (General Law of Health) but unenforced for indigenous groups.

*Psilocybe* mushrooms contain approximately 2-3 mg of psilocybin (4-phosphoryloxy-DMT) per gram of dry-weight mushrooms. The potency of psilocybin, relative to LSD, is approximately 1:100, the typical


dose of psilocybin is 5-15 mg. According to its chemical structure, psilocybin is a tryptamine. When hydrolyzed, it produces psilocin (4-hydroxy-DMT), whose hallucinogenic properties are almost 2 times stronger than the parent compound. Psilocybin-induced effects become evident after 20-30 min of mushroom ingestion and reach peak effects within 2-3 h, which lines up with the maximum psilocin concentration in the bloodstream. The half-life of psilocin is approximately 1.5 h, and the mushroom-induced experience generally lasts 4-6 h. Psilocin effects are dose-dependent and include disorganized thought processes, emotional changes, synesthesia, euphoria, sensory illusions, and auditory and visual hallucinations. Since psilocin also alters time perception, users may undergo a non-ending experience, which could be unpleasant. After *Psilocybe* mushroom consumption, nausea, vomiting, and transient headaches are common<sup>15,16</sup>. Psilocin is a serotonin transporter inhibitor and a partial agonist of the 5-HT<sub>2A</sub> receptors but also has an affinity in the nanomolar or micromolar range for the 5-HT<sub>2C</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, D<sub>1</sub>, and D<sub>2</sub> receptors (Table 1).

## PEYOTE - Mescaline

Peyote (*Lophophora williamsii*) is a small cactus with hallucinogen effects traditionally used as a sacred plant by native populations from the central and northern part of Mexico (huicholes and raramuries, respectively), native American populations from the United States and some First Nations in Canada. Mescaline (3,4,5-trimethoxyphenethylamine) is the psychoactive substance of peyote and produces effects similar to other classic hallucinogens, including the distortion of thinking processes, sense of time, and self-awareness. In addition, the sense of smell might be enhanced, and visual phenomena occur with closed and open eyes. A unique characteristic of mescaline is the tendency to perceive colorful, symmetrical, and geometric patterns/shapes as in a Cubist painting. Users also believe that they can trespass the limits of Earth, time, and space<sup>17</sup>.

Peyote tastes bitter, producing intense nausea and vomiting when swallowed. As it occurs with ayahuasca, these effects can be interpreted as a symbolic cleaning phase during the ritual use of the cactus. Peyote can be sun-dried and powdered in 30-150 mg

Figure 2. Representation of classic hallucinogens' pharmacological profile, depicting their affinity ( $K_i$  values) to different receptors (based on data from Table 1).



doses. Another form of use is eating fresh buttons or diluting the powdered peyote to drink. The active oral doses of mescaline are between 150 and 700 mg, making it considerably less potent than LSD and psilocybin. In addition, mescaline has a slow onset of action, 2-4 h, and its effects last from 10 to 14 h. Because mescaline is a phenethylamine, it produces stimulant actions like amphetamine or MDMA, including increased heart rate, blood pressure, and pupil dilation. Mescaline is the less potent serotonergic hallucinogen with affinity, in the micromolar range, for the 5HT<sub>1A</sub>, 5HT<sub>2A</sub>, 5HT<sub>2C</sub>, TAAR<sub>1</sub>, D<sub>1</sub>, and D<sub>2</sub> receptors, among others<sup>18</sup> (Table 1).

## MECHANISM OF ACTION OF CLASSIC HALLUCINOGENS

As mentioned, classic hallucinogens generally activate the serotonergic system, binding to several receptors, including 5-HT<sub>1</sub>, 5-HT<sub>2A/B/C</sub>, 5-HT<sub>5</sub>, 5-HT<sub>6</sub>, and 5-HT<sub>7</sub>,

but it is mainly the 5-HT<sub>2A</sub> receptor activation what mediates the hallucinatory experience. In humans, the selective blockage of 5-HT<sub>2A</sub> receptors with ketanserin abolishes perceptual and subjective effects induced by psilocybin<sup>19</sup>. Similarly, ketanserin prevents the neurochemical and behavioral changes produced by classic hallucinogens in animal models. Furthermore, transgenic mice lacking 5-HT<sub>2A</sub> receptors do not express the typical head-shake behavior produced by hallucinogens; however, this behavior reappears after restoring the expression of 5-HT<sub>2A</sub> receptors<sup>20</sup>. It is worth mentioning that not all 5-HT<sub>2A</sub> receptor agonists have hallucinogenic properties. Classic hallucinogens and non-hallucinogenic 5-HT<sub>2A</sub> receptor agonists activate different intracellular pathways in cortical pyramidal neurons. In addition to the serotonergic receptors' activation produced by LSD, it also shows intrinsic activity on dopamine D<sub>1</sub>, D<sub>2</sub>, and  $\alpha$ -adrenergic receptors (Fig. 2). It is believed that the initial effects of LSD are directly related to the activation of the serotonergic system. However, there is a

delayed activation of the dopaminergic system<sup>21</sup> that might be related to the so-called “bad trips” in humans since they generally occur several hours after LSD intake.

## EFFECTS OF THE DISSOCIATIVE ANESTHETIC KETAMINE

The first dissociative anesthetic was PCP. Developed initially as an analgesic, PCP was in use until 1967 in the United States, when it was discontinued due to severe adverse effects in some patients, including dysphoria and psychosis. Ketamine was synthesized in 1962 and marketed as a human anesthetic in 1970. Today, ketamine is still used for patients in several countries and as a veterinary anesthetic worldwide. In addition to the effects common to classic serotonergic hallucinogens, ketamine can produce out-of-the-body experiences (feeling detached from the environment and oneself), confusion, vivid dreams, and near-death experiences. It is misused at subanesthetic doses, snorted, and sometimes injected (i.m.) or swallowed<sup>4</sup>. Ketamine is a mixture of two enantiomers (S)-ketamine and (R)-ketamine. (S)-ketamine produces more analgesia, less salivation, and less delirium than (R)-ketamine. Under control settings and at the proper doses, ketamine and (S)-ketamine (esketamine) are effective novel antidepressant drugs, especially for people with suicidal thoughts and in combination with other traditional antidepressants<sup>24</sup>.

## MECHANISM OF ACTION OF KETAMINE

Ketamine has a complex mechanism of action. It is a non-competitive antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor (NMDAR). NMDARs are ionic channels of different subunit compositions: GluN1, GluN2, and GluN3. NMDARs typically have two GluN1 subunits and GluN2 or GluN3 subunits. Ketamine has a high affinity for NMDAR with GluN2D subunits, which are abundant in GABAergic neurons and indirectly activates 5-HT<sub>2A</sub> receptors<sup>25</sup>. According to the glutamatergic disinhibition hypothesis, glutamate release increases in cortical and subcortical brain regions when ketamine or other NMDA receptor antagonists block the NMDARs expressed in GABAergic neurons. Glutamate activates pyramidal neurons in

the prefrontal cortex (PFC) that send their projections to the Raphe Nucleus and stimulate serotonergic neurons, which, in turn, send projections back to the PFC where serotonin directly activates 5-HT<sub>2A</sub> receptors<sup>26</sup>. Ketamine also has other mechanisms of action independent of NMDAR inhibition. Among them, ketamine activates the mTORC1 pathway. mTORC1 stands for mechanistic target of rapamycin complex 1. Mechanistic TOR (formerly called “mammalian” TOR) is a protein kinase inhibited by rapamycin, an antibiotic with immunosuppressant effects. mTORC1 is a protein complex that regulates cell metabolism and growth by promoting protein and lipid synthesis, suppressing autophagy, and modulating lysosomal biogenesis<sup>27</sup>. In addition, mTORC1 regulates neural development. Other NMDAR-independent actions of ketamine include increased brain-derived neurotrophic factor (BDNF) plasma levels<sup>28</sup>. BDNF promotes neuronal survival and facilitates long-term potentiation. It has been associated with plastic changes in learning and memory and is essential to cognitive function. Dysregulation of BDNF and other neurotrophic factors has been associated with several pathologies, including major depressive disorder (MDD)<sup>29</sup>. In addition, ketamine inhibits GluN2B-containing NMDARs in astrocytes (reviewed in<sup>25</sup>). Recent evidence supports that NMDAR antagonism and non-NMDA ketamine actions are involved in ketamine’s antidepressant effects<sup>21</sup>.

## RISKS ASSOCIATED WITH HALLUCINOGEN DRUG USE

The adverse effects shared by different hallucinogens include the “hallucinogen persisting perceptual disorder” (HPPD), drug interactions, and potential adverse cardiac effects. The most recent version of the diagnostic and statistical manual for psychiatric disorders (DSM-5) includes the description of HPPD, which refers to the re-experience of the perceptual changes (“flashbacks”) a long time after cessation of the drug consumption, which is sufficiently intense to cause a serious disturbance or impairment in function<sup>30</sup>. The flashbacks can be unpleasant and emotionally traumatic and may co-occur with physical changes, including nausea, vomiting, mydriasis, headache, and drowsiness.

Several drug interactions between classic hallucinogens and other drugs have been described. For

example, the combination of hallucinogens and lithium or tricyclic antidepressants (TCAs) exacerbates the neurochemical changes produced by hallucinogens. As a result, this drug combination intensifies the perceptual and emotional experience, which may increase the probability of panic attacks and transitory psychotic states<sup>31</sup>. In addition, the acute administration of SSRI or MAO inhibitors potentiates the response to LSD and can produce a serotonin syndrome<sup>32</sup>. This potentially life-threatening condition includes neuromuscular, autonomic, and cognitive symptoms. In the initial stage, individuals show agitation, insomnia, nausea, diarrhea, tremor, and dilated pupils; symptoms can progress to hyperreflexia, excessive sweating, and clonus. Patients with severe symptoms, such as body temperature over 38.5°C, confusion, delirium, sustained clonus, and rhabdomyolysis, must be referred to the hospital<sup>33</sup>.

Another negative long-term effect of hallucinogens use is the chronic activation of 5-HT<sub>2B</sub> receptors in the heart, which can produce valvular heart disease (VHD). Due to tolerance development, users are unlikely to consume hallucinogens daily; however, VHD could be a risk when hallucinogens are consumed in a “microdosing” regimen, in which users consume a low (but not neglectable) dose every day, sometimes multiple times a day<sup>34</sup>.

As to ayahuasca’s risk effects, people with gastrointestinal disorders can have them exacerbated due to vomit and diarrhea. This can produce a severe electrolyte imbalance requiring immediate medical attention. In addition, people with a personal or familial history of psychiatric disorders are more vulnerable to having a psychotic experience<sup>35</sup>.

Although not very common, one of the risks related to psilocybin-mushrooms consumption is a toxic response that includes gastrointestinal symptoms, hypertension, hyperreflexia, tachycardia, and liver or renal failure. Mushroom poisoning may require medical intervention or emergency hospitalization. As it occurs with ayahuasca, hallucinogenic mushrooms may also precipitate some forms of psychosis in people with a family history of psychiatric disorders<sup>7</sup>.

Users, after mescaline intake, may also show signs of a toxic syndrome including hyperreflexia, tachycardia, ataxia, seizures, mydriasis, sialorrhea, hyperthermia,

and paresthesia. Due to its long-lasting effects, mescaline can produce a prolonged psychotic state with schizophrenia-like symptoms. Although extremely rare, peyote ingestion might cause damage to the lower esophagus tissue due to severe vomiting<sup>17</sup>.

Ketamine, at high doses, produces hypertension, tachycardia, chest pain, anesthesia, muscular rigidity, anxiety, paranoia, and psychosis, without loss of consciousness. This intoxication is usually known as the K-hole. Besides being very unpleasant, it makes people vulnerable to injuries and attacks due to losing body sensations and the inability to move. Ketamine produces tolerance and, unlike classic hallucinogens, it has high dependence liability. In addition, long-term use of ketamine can produce bladder and liver toxicity<sup>36</sup>.

## THERAPEUTIC POTENTIAL OF HALLUCINOGENS

The initial research analyzing the potential therapeutic value of classic hallucinogens conducted in the 1950s and 1960s had low scientific standards and questionable methodology, mainly due to poor standardized diagnostic techniques. During the recent “second wave” of psychedelics research, the studies aimed for more rigorous experimental designs and higher criticism of results. In 2006, a double-blind, randomized, and controlled study conducted on healthy subjects described that a high dose of psilocybin (30 mg) significantly improved psychological well-being over 2 months<sup>37</sup>. The subsequent studies mainly focused on psilocybin’s potential benefits in patients with anxiety, depression, and emotional suffering and distress associated with a terminal illness (cancer). For example, Moreno *et al.* 2006, described the reduction of clinical symptoms in patients diagnosed with obsessive-compulsive disorder after receiving up to four psilocybin sessions<sup>38</sup>. In another study with a randomized crossover design, psilocybin significantly reduced the psychiatric distress of patients with advanced-stage cancer<sup>39,40</sup>. In addition, administering two doses of psilocybin (10 and 25 mg) to patients with treatment-resistant depression significantly reduced depressive symptoms throughout 6-months<sup>41</sup>. Other studies have shown that psilocybin increases abstinence in patients with alcohol and nicotine dependence<sup>42,43</sup>. Although these studies reported positive results, the therapeutic potential of

hallucinogens remains controversial due to the lack of proper control conditions, discrepancies in the dose administered based on participants' weight variability, the difficulty of conducting double-blind studies, and other methodologic variables. Recent studies have shown that low doses of several hallucinogen compounds have therapeutical potential as antidepressant drugs. According to the DSM 5, the criteria for diagnosing MDD include the occurrence of five or more of the following symptoms in a week, not attributable to other medical conditions: depressed mood, loss of interest and pleasure in daily activities, changes in body weight (loss or gain), sleep disturbances, fatigue, restlessness or psychomotor retardation, feeling worthless or excessive guilt, decreased concentration, suicidal thoughts, or attempts. In addition, it is necessary to rule out a history of manic or hypomanic episodes and consider that depression in children and adolescents may include irritable mood<sup>30</sup>.

Because complex alterations in neurotransmitter levels occur in MDD, different classes of antidepressants exist with various mechanisms of action: Monoamine oxidase inhibitors, TCAs, atypical antidepressants, serotonin modulators, serotonin-norepinephrine reuptake inhibitors, and SSRIs. Each class has a different pharmacological profile and side effects. Despite their efficacy and wide clinical use, these medications usually take weeks or months to produce their therapeutic effect, and some people remain unresponsive to them.

Preclinical studies conducted in the 1900s showed that NMDAR inhibition produced antidepressant-like effects in rodents, suggesting that NMDAR could be a target for antidepressant medications in humans. Later, Berman and coworkers reported that a 40-min infusion of ketamine (0.5 mg/kg) at a subanesthetic dose produced clear antidepressant effects 4 h after infusion in patients with MDD<sup>44</sup>. Because ketamine's rapid onset of action might provide a significant advantage for patients having suicidal ideations, other clinical trials followed soon, confirming the efficacy of ketamine in producing antidepressant actions in patients unresponsive to other pharmacotherapies. Ketamine has also proved effective in patients with bipolar depression. Ketamine and the available esketamine nasal spray are usually combined with other antidepressant drugs. Due to the high dependence liability of ketamine, its use requires medical supervision.

Although there is evidence that administering ayahuasca decoction to patients with resistant MDD improves their clinical symptoms up to 21 days after the infusion intake<sup>45</sup>, scientific evidence supporting the therapeutic effect of DMT is scarce. The main limitation is the variability of ingredients in the ayahuasca drink used in clinical settings. Therefore, future studies using pharmacologically pure compounds are needed to determine if controlled and supervised ayahuasca use has therapeutic effects.

## CONCLUSION

The interest in studying the potential therapeutic effects of hallucinogens emerged in the 1950s and 1960s but yielded non-conclusive results and stopped for more than two decades. The current interest in this topic warrants preclinical and clinical unbiased research using a rigorous and validated methodology in controlled settings to determine hallucinogens' efficacy and safety profile. This is particularly important because non-medical hallucinogen use appears to be outpacing evidence-based research. In addition, the microdosing practice to allegedly enhance creativity, productivity, and mood has become increasingly popular. Clinical trials should address concerns about long-term effects and potential risks associated with psychedelics consumption, such as psychiatric sequelae in vulnerable populations and the possibility of experiencing a serotonin syndrome due to some drug-drug interactions.

There is evidence that hallucinogens, especially ketamine, have antidepressant effects in people with MDD resistant to other treatments and in people with suicidal ideations, requiring a fast-acting antidepressant agent. However, current data supporting the effectiveness of psychedelic compounds in treating some psychiatric conditions are limited. Beyond doubt, psychedelic research will continue growing with unbiased studies and higher rigorous methodologic standards.

## REFERENCES

1. Bonson KR. Regulation of human research with LSD in the United States (1949-1987). *Psychopharmacology (Berl)*. 2018;235:591-604.
2. Livne O, Shmulewitz D, Walsh C, Hasin DS. Adolescent and adult time trends in US hallucinogen use, 2002-19: any use, and use of ecstasy, LSD and PCP. *Addiction*. 2022;117:3099-109.

3. Kelmendi B, Kaye AP, Pittenger C, Kwan AC. Psychedelics. *Curr Biol*. 2022;32:R63-7.
4. Pelletier R, Le Dare B, Le Bouedec D, Kernalleguen A, Ferron PJ, Morel I, et al. Arylcyclohexylamine derivatives: pharmacokinetic, pharmacodynamic, clinical and forensic aspects. *Int J Mol Sci*. 2022;23:15574.
5. Nour MM, Carhart-Harris RL. Psychedelics and the science of self-experience. *Br J Psychiatry*. 2017;210:177-9.
6. Mason NL, Kuypers KP, Muller F, Reckweg J, Tse DH, Toennes SW, et al. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. *Neuropsychopharmacology*. 2020;45:2003-11.
7. Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. The therapeutic potential of psilocybin. *Molecules*. 2021;26:2948.
8. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. The pharmacology of lysergic acid diethylamide: a review. *CNS Neurosci Ther*. 2008;14:295-314.
9. Liechti ME. Modern clinical research on LSD. *Neuropsychopharmacology*. 2017;42:2114-27.
10. Simmler LD, Buchy D, Chaboz S, Hoener MC, Liechti ME. In Vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1. *J Pharmacol Exp Ther*. 2016;357:134-44.
11. Hamill J, Hallak J, Dursun SM, Baker G. Ayahuasca: psychological and physiologic effects, pharmacology and potential uses in addiction and mental illness. *Curr Neuropharmacol*. 2019;17:108-28.
12. Simao AY, Goncalves J, Duarte AP, Barroso M, Cristovao AC, Gallardo E. Toxicological aspects and determination of the main components of ayahuasca: a critical review. *Medicines (Basel)*. 2019;6:106.
13. Rossi GN, Guerra LT, Baker GB, Dursun SM, Saiz JC, Hallak JE, et al. Molecular pathways of the therapeutic effects of ayahuasca, a botanical psychedelic and potential rapid-acting antidepressant. *Biomolecules*. 2022;12:1618.
14. Estrella-Parra EA, Almanza-Perez JC, Alarcon-Aguilar FJ. Ayahuasca: uses, phytochemical and biological activities. *Nat Prod Bioprospect*. 2019;9:251-65.
15. Reiff CM, Richman EE, Nemeroff CB, Carpenter LL, Widge AS, Rodriguez CI, et al. Psychedelics and psychedelic-assisted psychotherapy. *Am J Psychiatry*. 2020;177:391-410.
16. Holze F, Becker AM, Kolaczynska KE, Duthaler U, Liechti ME. Pharmacokinetics and pharmacodynamics of oral psilocybin administration in healthy participants. *Clin Pharmacol Ther*. 2023;113:822-31.
17. Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions. *Curr Mol Pharmacol*. 2019;12:184-94.
18. Vamvakopoulou IA, Narine KA, Campbell I, Dyck JR, Nutt DJ. Mescaline: the forgotten psychedelic. *Neuropharmacology*. 2023;222:109294.
19. Aghajanian GK, Marek GJ. Serotonin and hallucinogens. *Neuropsychopharmacology*. 1999;21(2 Suppl):16S-23S.
20. Canal CE, Morgan D. Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. *Drug Test Anal*. 2012;4:556-76.
21. De Gregorio D, Aguilar-Valles A, Preller KH, Heifets BD, Hibicke M, Mitchell J, et al. Hallucinogens in mental health: preclinical and clinical studies on LSD, psilocybin, MDMA, and ketamine. *J Neurosci*. 2021;41:891-900.
22. Carbonaro TM, Gatch MB. Neuropharmacology of N,N-dimethyltryptamine. *Brain Res Bull*. 2016;126:74-88.
23. De Gregorio D, Comai S, Posa L, Gobbi G. d-Lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology. *Int J Mol Sci*. 2016;17:1953.
24. Psiuk D, Nowak EM, Dycha N, Lopuszanska U, Kurzepa J, Samardakiewicz M. Esketamine and psilocybin-the comparison of two mind-altering agents in depression treatment: systematic review. *Int J Mol Sci*. 2022;23:11450.
25. Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. *Mol Psychiatry*. 2018;23:801-11.
26. Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. *Nat Rev Neurosci*. 2010;11:642-51.
27. Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. *Cell*. 2017;169:361-71.
28. Woelfer M, Li M, Colic L, Liebe T, Di X, Biswal B, et al. Ketamine-induced changes in plasma brain-derived neurotrophic factor (BDNF) levels are associated with the resting-state functional connectivity of the prefrontal cortex. *World J Biol Psychiatry*. 2020;21:696-710.
29. Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-derived neurotrophic factor: a key molecule for memory in the healthy and the pathological brain. *Front Cell Neurosci*. 2019;13:363.
30. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. United States: American Psychiatric Association.
31. Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. *Behav Brain Res*. 1996;73:229-33.
32. Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. *Neuropsychopharmacology*. 1996;14:425-36.
33. Foong AL, Grindrod KA, Patel T, Kellar J. Demystifying serotonin syndrome (or serotonin toxicity). *Can Fam Physician*. 2018;64:720-7.
34. Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, et al. Microdosing psychedelics: more questions than answers? An overview and suggestions for future research. *J Psychopharmacol*. 2019;33:1039-57.
35. Dos Santos RG, Bouso JC, Hallak JE. Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. *Ther Adv Psychopharmacol*. 2017;7:141-57.
36. Jelen LA, Stone JM. Ketamine for depression. *Int Rev Psychiatry*. 2021;33:207-28.
37. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology (Berl)*. 2006;187:268-83; discussion 284-92.
38. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. *J Clin Psychiatry*. 2006;67:1735-40.
39. Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Arch Gen Psychiatry*. 2011;68:71-8.
40. Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *J Psychopharmacol*. 2016;30:1165-80.
41. Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. *N Engl J Med*. 2021;384:1402-11.
42. Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laszka E, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. *JAMA Psychiatry*. 2022;79:953-62.
43. Jones G, Lipson J, Nock MK. Associations between classic psychedelics and nicotine dependence in a nationally representative sample. *Sci Rep*. 2022;12:10578.
44. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. *Biol Psychiatry*. 2000;47:351-354.
45. Sanches RF, de Lima Osorio F, Dos Santos RG, Macedo LR, Maia-de-Oliveira JP, Wichert-Ana L, et al. Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study. *J Clin Psychopharmacol*. 2016;36:77-81.